MedTrace Logo

Qatar Cardiometabolic Retrospective Cohort-Analysis Using Artificial Intelligence

NCT07515807 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 10000

Last updated 2026-04-21

No results posted yet for this study

Summary

Cardiovascular disease is the leading cause of death worldwide, and individuals with diabetes or other cardiometabolic conditions are at increased risk of adverse cardiovascular outcomes. Although advances in prevention and treatment have reduced cardiovascular events globally, cardiometabolic disease continues to represent a significant health burden, particularly in regions with high diabetes prevalence. In Qatar and other Gulf Cooperation Council countries, the prevalence of diabetes and obesity is increasing, contributing to a high proportion of participants presenting with acute coronary syndrome who have type 2 diabetes or prediabetes. This observational study will use electronic medical record data from patients hospitalized at the Heart Hospital with acute coronary syndrome and a concomitant diagnosis of diabetes or prediabetes. The study will assess trends in cardiovascular risk factors and cardiovascular events, including readmission and mortality. An artificial intelligence component will be used to develop and validate machine learning based risk prediction models to forecast adverse cardiovascular outcomes in participants with cardiometabolic disease. These models will integrate clinical, biochemical, imaging, and other non-invasive data routinely collected during participants care to identify predictors of cardiovascular events.

Conditions

  • Cardio Vascular Disease
  • Acute Coronary Syndromes (ACS)
  • Type 2 Diabetes
  • Pre Diabetes
  • Artifical Intelligence

Sponsors & Collaborators

  • Hamad Medical Corporation

    collaborator INDUSTRY

  • Weill Cornell Medical College in Qatar

    lead OTHER

Principal Investigators

  • Charbel Abi Khalil · Weill Cornell Medicine-Qatar

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-16
Primary Completion
2030-07-16
Completion
2030-07-16

Countries

  • Qatar

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07515807 on ClinicalTrials.gov